Canaccord Genuity analyst Jason Mills maintained a Buy rating on Cryolife (NYSE: CRY) today and set a price target of $28. The company’s shares opened today at $21.90.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 24.0% and a 78.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.
Cryolife has an analyst consensus of Moderate Buy, with a price target consensus of $25.75.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $52.83 million and GAAP net loss of $3.01 million. In comparison, last year the company earned revenue of $45.06 million and had a net profit of $2.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
